TOP TEN perturbations for 39247_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39247_at
Selected probe(set): 215559_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39247_at (215559_at) across 6674 perturbations tested by GENEVESTIGATOR:
hepatocyte (ESC) / HepaRG
Relative Expression (log2-ratio):-4.4819975Number of Samples:8 / 12
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | HepaRG |
| Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
collecting duct carcinoma study 1 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-3.7438087Number of Samples:2 / 3
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
hepatocyte (ESC) / Hep-G2
Relative Expression (log2-ratio):-3.69938Number of Samples:8 / 9
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | Hep-G2 |
| Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: |
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG) / vehicle (DMSO) treated HepaRG cell sample
Relative Expression (log2-ratio):-3.4631176Number of Samples:3 / 12
| Experimental | 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG) |
| HepaRG cells exposed to 7500 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Chemical was added at day 19 of cultivation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:--- | |
| Control | vehicle (DMSO) treated HepaRG cell sample |
| HepaRG cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Firstly, cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Then the vehicle was added. |
renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue (adult)
Relative Expression (log2-ratio):-3.2348213Number of Samples:4 / 3
| Experimental | renal cell carcinoma study 6 (chromophobe type) |
| Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC). | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
nephroblastoma study 2 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-2.945426Number of Samples:4 / 3
| Experimental | nephroblastoma study 2 |
| Tumor tissue samples from the kidney of patients with Wilms’ tumor. | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
breast cancer study 8 (metastatic) / normal breast tissue
Relative Expression (log2-ratio):-2.9210558Number of Samples:2 / 4
| Experimental | breast cancer study 8 (metastatic) |
| Human metastatic infiltrating ductal carcinoma sample of the breast derived from lymph nodes of a female patient with breast cancer. | |
| Control | normal breast tissue |
| Normal human breast samples of healthy female individuals. |
HCC study 23 (portal vein infiltration) / adjacent liver tissue
Relative Expression (log2-ratio):-2.8533201Number of Samples:3 / 10
| Experimental | HCC study 23 (portal vein infiltration) |
| Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) with portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai. | |
| Control | adjacent liver tissue |
| Normal adjacent liver tissue samples derived from patients with hepatocellular carcinoma (HCC). Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)
Relative Expression (log2-ratio):2.8013067Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (confluent) |
| Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):2.7076483Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
Organism: Homo sapiens
Gene: 39247_at
Selected probe(set): 214033_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39247_at (214033_at) across 6674 perturbations tested by GENEVESTIGATOR:
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):4.6216307Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)
Relative Expression (log2-ratio):4.450279Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (confluent) |
| Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert. |
collecting duct carcinoma study 1 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-3.5764084Number of Samples:2 / 3
| Experimental | collecting duct carcinoma study 1 |
| Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary) / expO cervical cancer study 1 (mucinous adenocarcinoma, endocervical type; primary)
Relative Expression (log2-ratio):-3.5524254Number of Samples:3 / 2
| Experimental | expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary) |
| Primary tumor tissue samples obtained from the cervix uteri of patients with squamous cell carcinoma, keratinizing type (NOS). | |
| Control | expO cervical cancer study 1 (mucinous adenocarcinoma, endocervical type; primary) |
| Primary tumor tissue samples obtained from the cervix uteri of patients with mucinous adenocarcinoma, endocervical type. |
nephroblastoma study 2 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-3.4349174Number of Samples:4 / 3
| Experimental | nephroblastoma study 2 |
| Tumor tissue samples from the kidney of patients with Wilms’ tumor. | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic) / renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-3.417941Number of Samples:2 / 18
| Experimental | renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted). |
Barrett's esophagus study 3 / normal esophageal epithelium sample
Relative Expression (log2-ratio):3.3508883Number of Samples:17 / 18
| Experimental | Barrett's esophagus study 3 |
| Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection. | |
| Control | normal esophageal epithelium sample |
| Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy. |
rapidly progressive glomerulonephritis; ANCA-associated vasculitis study 5 (tubulointerstitium) / focal segmental glomerulosclerosis study 9 (glomerulus)
Relative Expression (log2-ratio):3.2292356Number of Samples:21 / 10
| Experimental | rapidly progressive glomerulonephritis; ANCA-associated vasculitis study 5 (tubulointerstitium) |
| Tubulointerstitium tissue sample obtained by microdissection from kidney biopsy, from patients suffering from rapidly progressive glomerulonephritis and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Donors were positive for ANCA-antibody. Biopsy samples were obtained from the European Renal cDNA Bank-Kroener-Fresenius biopsy bank. All biopsies were stratified by a reference pathologist. | |
| Control | focal segmental glomerulosclerosis study 9 (glomerulus) |
| Glomeruli tissue sample obtained by microdissection from kidney biopsy, from patients suffering from focal segmental glomerulosclerosis. Biopsy samples were obtained from the European Renal cDNA Bank-Kroener-Fresenius biopsy bank. All biopsies were stratified by a reference pathologist. |
AsPC-1 / BxPC-3
Relative Expression (log2-ratio):3.2287254Number of Samples:3 / 3
| Experimental | AsPC-1 |
| Human xenograft derived metastatic cancer cell line derived from mouse xenografts initiated with metastatic cells from the ascites derived from a 62 years old female Caucasian patient with pancreatic adenocarcinoma. Synonyms:AsPc-1; Aspc-1; ASPC-1; As-PC1; ASPC1; AsPC1; Aspc1; AsPc1 Cellosaurus code: | |
| Control | BxPC-3 |
| Human pancreatic adenocarcinoma cell line derived from a 61 years old female patient. Synonyms:BxPc-3; BXPC-3; Bx-PC3; BXPC3; BxPC3; BxPc3 Cellosaurus code: |
expO cervical cancer study 1 (squamous cell carcinoma, NOS; primary) / expO cervical cancer study 1 (mucinous adenocarcinoma, endocervical type; primary)
Relative Expression (log2-ratio):-3.2221699Number of Samples:15 / 2
| Experimental | expO cervical cancer study 1 (squamous cell carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the cervix uteri of patients with squamous cell carcinoma (NOS). | |
| Control | expO cervical cancer study 1 (mucinous adenocarcinoma, endocervical type; primary) |
| Primary tumor tissue samples obtained from the cervix uteri of patients with mucinous adenocarcinoma, endocervical type. |
Organism: Homo sapiens
Gene: 39247_at
Selected probe(set): 236205_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39247_at (236205_at) across 6674 perturbations tested by GENEVESTIGATOR:
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG) / vehicle (DMSO) treated HepaRG cell sample
Relative Expression (log2-ratio):-4.0046244Number of Samples:3 / 12
| Experimental | 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG) |
| HepaRG cells exposed to 7500 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Chemical was added at day 19 of cultivation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:--- | |
| Control | vehicle (DMSO) treated HepaRG cell sample |
| HepaRG cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Firstly, cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Then the vehicle was added. |
hepatocyte (ESC) / Hep-G2
Relative Expression (log2-ratio):-3.3320932Number of Samples:8 / 9
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | Hep-G2 |
| Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: |
hepatocyte (ESC) / HepaRG
Relative Expression (log2-ratio):-3.1560202Number of Samples:8 / 12
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | HepaRG |
| Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
PMA study 7 (12h) / vehicle (DMSO) treated HepG2 cell sample
Relative Expression (log2-ratio):-2.7181273Number of Samples:2 / 12
| Experimental | PMA study 7 (12h) |
| HepG2 cells exposed to 500nM phorbol-12-myristat-13-acetate [(PMA ortetradecanoyl phorbol acetate (TPA)] in DMSO solvent for 12 hours. ATC code:--- | |
| Control | vehicle (DMSO) treated HepG2 cell sample |
| HepG2 cells exposed to DMSO solvent for 12 hours. |
hepatocyte-like cell differentiation study 1 (15d) / hepatocyte-like cell differentiation study 1 (5d)
Relative Expression (log2-ratio):2.575656Number of Samples:3 / 3
| Experimental | hepatocyte-like cell differentiation study 1 (15d) |
| Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2. | |
| Control | hepatocyte-like cell differentiation study 1 (5d) |
| Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days. |
HCC study 20 (CDX; Hep-G2; orthotopic) / HCC study 20 (PDX; orthotopic)
Relative Expression (log2-ratio):-2.5420866Number of Samples:5 / 11
| Experimental | HCC study 20 (CDX; Hep-G2; orthotopic) |
| Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks. | |
| Control | HCC study 20 (PDX; orthotopic) |
| Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks. |
HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)
Relative Expression (log2-ratio):-2.4618874Number of Samples:3 / 11
| Experimental | HCC study 20 (CDX; Hep-G2; ectopic) |
| Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. | |
| Control | HCC study 20 (PDX; ectopic) |
| Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. |
NCI-H358 / HCC827
Relative Expression (log2-ratio):-2.4314003Number of Samples:6 / 6
| Experimental | NCI-H358 |
| Human bronchioloalveolar carcinoma derived cell line. Synonyms:H358; H-358 Cellosaurus code: | |
| Control | HCC827 |
| Human primary cancer cell line derived from the lung of a patient with non-small-cell lung cancer. Synonyms:HCC-827; HCC0827 Cellosaurus code: |
HCC827 / A-549
Relative Expression (log2-ratio):2.321672Number of Samples:6 / 6
| Experimental | HCC827 |
| Human primary cancer cell line derived from the lung of a patient with non-small-cell lung cancer. Synonyms:HCC-827; HCC0827 Cellosaurus code: | |
| Control | A-549 |
| Human primary cancer cell line derived from the lung of a patient with carcinoma. Synonyms:A 549; A549; NCI-A549; A549/ATCC; hA549 Cellosaurus code: |
azathioprine study 8 (48h) / vehicle (DMSO) treated HepG2 cell sample
Relative Expression (log2-ratio):-2.320777Number of Samples:2 / 19
| Experimental | azathioprine study 8 (48h) |
| HepG2 cells exposed to 250μM azathioprine in DMSO solvent for 48 hours. ATC code: | |
| Control | vehicle (DMSO) treated HepG2 cell sample |
| HepG2 cells exposed to DMSO solvent for 48 hours. |